Leukodystrophy, Metachromatic clinical trials
The registry lists 49 studies for Leukodystrophy, Metachromatic across more than 10 countries. 11 are recruiting or about to start. 23 of them are mainly about Leukodystrophy, Metachromatic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.
Get an email when these change. Save the Leukodystrophy, Metachromatic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Shire (7) · Masonic Cancer Center, University of Minnesota (6) · Orchard Therapeutics (3) · Talaris Therapeutics Inc. (3) · Assistance Publique - Hôpitaux de Paris (3) · Magenta Therapeutics, Inc. (2) · Shenzhen Geno-Immune Medical Institute (2) · Children's Hospital of Philadelphia (2)
What is being tested here
Drugs under test in Leukodystrophy, Metachromatic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Alemtuzumab | 1 | 0 | 4 |
| Melphalan | 1 | 0 | 2 |
| Hydroxyurea | 1 | 0 | 1 |
| Fludarabine | 1 | 0 | 1 |
| Thiotepa | 1 | 0 | 1 |
| Cebsulfase alfa | 0 | 0 | 4 |
| HGT-1111 | 0 | 0 | 3 |
| Cyclophosphamide | 0 | 1 | 3 |
| Busulfan | 0 | 1 | 3 |
| Spanlecortemlocel | 0 | 0 | 2 |
Drug classes tested here Alkylating agents 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Nov 2026Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT · Paul Szabolcs
- Nov 2026Early Check: Expanded Screening in Newborns · RTI International
- Oct 2027UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells · Joanne Kurtzberg, MD
Who these studies take
Of the 8 Leukodystrophy, Metachromatic studies recruiting now, 3 (38%) set no upper age limit and 5 (63%) stop at 75 or younger. 7 (88%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 7 (88%) | 7 (88%) |
| 18 | 7 (88%) | 7 (88%) |
| 30 | 6 (75%) | 6 (75%) |
| 40 | 6 (75%) | 6 (75%) |
| 50 | 6 (75%) | 6 (75%) |
| 65 | 3 (38%) | 3 (38%) |
| 75 | 3 (38%) | 3 (38%) |
| 85 | 3 (38%) | 3 (38%) |
Across all 49 studies, recruiting or not: 78% stop at 75 or younger and 76% at 65; 96% take children; 4% are for women only and 2% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 49 of 49. search them.
- Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.RecruitingNCT048803561 country
- Direct Lentiviral Injection Gene Therapy for MLDNot yet recruitingNCT03725670Not applicable1 country
- Lentiviral Hematopoietic Stem Cell Gene Therapy for MLDNot yet recruitingNCT07046338Not applicable1 country
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931681 country
- UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like CellsRecruitingNCT02254863Phase 11 country
- ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening ProgramEnrolling by invitationNCT053680381 country
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICRecruitingNCT045283551 country
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 21 country
- The Myelin Disorders Biorepository ProjectRecruitingNCT030473691 country
- Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented GliaRecruitingNCT049253491 country
- Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and AdrenoleukodystrophyRecruitingNCT02559830Phase 1/21 country
- MT2013-31: Allo HCT for Metabolic Disorders and Severe OsteopetrosisActive, not recruitingNCT02171104Phase 21 country
- A Study of Intrathecal SHP611 in Children With Metachromatic LeukodystrophyCompletedNCT03771898Phase 214 countries
- Early Check: Expanded Screening in NewbornsActive, not recruitingNCT036552231 country
- An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic LeukodystrophyCompletedNCT01887938Phase 1/27 countries
- Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell TransplantationCompletedNCT01303146Phase 21 country
- A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)CompletedNCT03392987Phase 21 country
- Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic LeukodystrophyCompletedNCT01801709Phase 1/21 country
- Gene Therapy for Metachromatic Leukodystrophy (MLD)CompletedNCT01560182Phase 1/21 country
- Imaging Study of the White Matter Lesions in Children With Metachromatic LeucodystrophyCompletedNCT01325025Not applicable1 country
- LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for LeukodystrophiesCompletedNCT026991901 country
- OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)Active, not recruitingNCT04283227Phase 31 country
- Baby Detect : Genomic Newborn ScreeningCompletedNCT056874741 country
- The Natural History of Metachromatic Leukodystrophy Study (HOME Study)CompletedNCT046283641 country
- The Natural History of Metachromatic LeukodystrophyWithdrawnNCT00639132
- A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in SpainWithdrawnNCT057555681 country
- Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic DisordersTerminatedNCT01372228Phase 1/21 country
- Human Placental-Derived Stem Cell TransplantationCompletedNCT01586455Phase 11 country
- Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)No longer availableNCT020841211 country
- MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)CompletedNCT03406962Phase 21 country
- Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)CompletedNCT00418561Phase 11 country
- Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)CompletedNCT00633139Phase 1/21 country
- Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)CompletedNCT01510028Phase 1/25 countries
- Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLDTerminatedNCT00681811Phase 21 country
- Natural History Study of Children With Metachromatic LeukodystrophyTerminatedNCT0196365010 countries
- A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456TerminatedNCT040088491 country
- Single Patient Expanded Access Protocol: Metabolic BoostNo longer availableNCT020212661 country
- BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 StudyNo longer availableNCT036398441 country
- Comparison of Acute Effect of Different Manual Techniques on Muscle Fascia StiffnessStatus unknownNCT04324775
- HSCT for High Risk Inherited Inborn ErrorsCompletedNCT00383448Phase 21 country
- Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)WithdrawnNCT02715505Phase 1/2
- Allogeneic Bone Marrow Transplant for Inherited Metabolic DisordersCompletedNCT01043640Phase 21 country
- Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of MetabolismTerminatedNCT00668564Phase 21 country
- Stem Cell Transplant for Inborn Errors of MetabolismCompletedNCT00176904Phase 2/31 country
- Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal DisordersCompletedNCT01626092Not applicable1 country
- ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic DiseasesTerminatedNCT00654433Phase 31 country
- Effect of Warfarin in the Treatment of Metachromatic LeukodystrophyCompletedNCT00683189Not applicable1 country
- Stem Cell Transplantation (SCT) for Genetic DiseasesCompletedNCT00004378Not applicable1 country
- Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT000059001 country